Author:
Kinnear Fiona J.,Hamilton-Shield Julian P.,Stensel David J.,Bayly Graham,Searle Aidan,Thackray Alice E.,Lithander Fiona E.
Abstract
Abstract
Background
Untreated heterozygous familial hypercholesterolaemia (FH) causes high low-density lipoprotein cholesterol (LDL-C) levels and increased cardiovascular disease (CVD) risk. Despite pharmacological treatment, many treated individuals remain at higher CVD risk than non-affected individuals. This may be due to LDL-C targets not being met and presence of other CVD risk factors. Adhering to dietary and physical activity (PA) recommendations developed for individuals with FH may further reduce CVD risk. However, there is insufficient research to support the efficacy of adhering to these guidelines on LDL-C and other CVD risk factors. The need for studies to investigate the effectiveness of nutrition and PA interventions in the FH population has been widely recognised and recommended. This paper describes the protocol of a pilot, randomised controlled trial designed to evaluate the feasibility and acceptability of a specifically developed nutrition and PA intervention aimed at improving the dietary intakes and PA levels of families with FH.
Methods
A two-arm randomised waitlist-controlled pilot trial will be conducted across three National Health Service (NHS) sites in England, UK. Twenty-four young people with FH, aged 10–18 years, and their affected parent, will be recruited and randomly assigned to the intervention or waitlist and usual care control. The primary aim is to provide evidence for the feasibility and acceptability of delivering the intervention, explored quantitatively (rates of recruitment, retention and outcome measure completeness) and qualitatively (qualitative interviews). The secondary aim is to provide evidence for the potential efficacy of the intervention on dietary intake, PA, sedentary time, body composition, CVD risk factors and quality of life determined at baseline and endpoint assessments. The intervention will involve an hour-long consultation with a dietitian at baseline and four follow-up contacts across the 12-week intervention. It has been specifically developed for use with individuals with FH and incorporates behavioural change techniques to target identified enablers and barriers to adherence in this population.
Discussion
This trial will estimate the feasibility and acceptability of the nutrition and PA intervention delivered to young people and parents with FH. If appropriate, this study can be used to inform the design of an adequately powered definitive trial.
Trial registration
ISRCTN, ISRCTN24880714. Registered 07/06/2018, http://www.isrctn.com/ISRCTN24880714.
Funder
National Institute for Health Research (NIHR) Bristol Biomedical Research Centre
Publisher
Springer Science and Business Media LLC
Reference84 articles.
1. Goldstein, J.H., HH; Brown, MS, Familial hypercholesterolemia, in The Metabolic and Molecular Bases of Inherited Disease, A. Sciver CR, Sly WS, Valle D. editors, Editor. 2001, McGraw-Hill: New York. p. 2863-2913.
2. Wong B, et al. Cardiovascular disease risk associated with familial hypercholesterolemia: a systematic review of the literature. Clin Ther. 2016;38(7):1696–709.
3. Akioyamen, L.E., et al., Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. BMJ Open, 2017. 7(9).
4. Neil A, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J. 2008;29(21):2625–33.
5. Hopkins, P.N., Putting into perspective the hazards of untreated familial hypercholesterolemia. Journal of the American Heart Association, 2017. 6(6).
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献